Drug Profile
AC 082
Alternative Names: AC-082Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Neurological-disorders(In volunteers) in Germany (PO, Capsule)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 06 Mar 2017 Actelion completes a phase I trial in Neurological disorders (In volunteers) in Germany (PO) (NCT02702648)